AHAbbey L. K. Hutton

Abbey L. K. Hutton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abbey L. K. Hutton has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Second-site capsule-locus mutations, not Ade efflux disruption, determine phage susceptibility across an Acinetobacter baumannii transposon mutant panel

    by Anita Tarasenko, Bhavya Papudeshi, Abbey L. K. Hutton, Maoge Zang, Brynley J. Davies, George Bouras, Vijini Mallawaarachchi, Bart A. Eijkelkamp, Robert A Edwards

    Resistance-Nodulation-Division (RND) efflux pumps have been implicated in phage adsorption in several Gram-negative bacteria, suggesting that AdeABC, AdeFGH and AdeIJK, the three characterised RND efflux systems of multidrug-resistant Acinetobacter baumannii, could play a similar role. We tested this hypothesis using five phages (Equilibrator, Taro, AT01, BB02, and AC03) and a panel of 13 A. baumannii strains, including nine AB5075 transposon mutants affecting AdeABC, AdeFGH, or AdeIJK. Host-range testing, efficiency-of-plating assays, capsule-associated density measurements, antimicrobial susceptibility testing, and whole-genome sequencing were performed to assess the relationship between genotype and phage infection. Overall, the data did not support a role for the Ade components as receptors. Phages Equilibrator, Taro and AT01 formed plaques on every strain, and the restricted host ranges of BB02 and AC03 did not correspond to disruption of a particular efflux system. Sequencing instead identified second-site mutations in the KL25 capsule locus in six of the ten AB5075 strains. These included a 1,998-bp deletion affecting wzc , substitutions in mnaA and mnaB , an IS Aba13 insertion in a putative glycosyltransferase and a subpopulation-associated frameshift in wzx . AC03 formed plaques on all six strains with capsule-locus changes but on none of the five strains without them. Capsule dependence differed among the other phages: relative to the parental AB5075, infection by these phages, Equilibrator, Taro and BB02, was restricted on the capsule-deficient wzc ::T26 strain, whereas AT01 efficiency was only slightly reduced. Insertion-site mapping also distinguished a near-terminal adeK insertion that retained the parental antimicrobial phenotype from an early adeK insertion associated with loss of AdeIJK function. Together, these findings identify capsule-locus variation as the strongest correlation with phage susceptibility in this panel and demonstrate the importance of verifying mutant genomes before assigning phenotypes to their annotated insertions. Impact statement: Transposon mutant collections are valuable for linking bacterial genes to phenotypes, but the recorded insertion does not necessarily describe every genetic change in a strain. We investigated whether the Ade efflux systems of A. baumannii contribute to phage susceptibility. Although the initial host-range patterns suggested differences among efflux mutants, whole-genome sequencing revealed independent capsule-locus mutations in six of ten AB5075 strains. Newly isolated phage AC03 formed plaques on every strain with a capsule-locus change and on none with wild-type capsule loci. This association explained differences between strains carrying separate insertions in the same ade genes. The other phages we isolated also differed in their dependence on capsule: some infected the capsule-deficient mutant poorly, whereas AT01 was comparatively unaffected. These results emphasise two considerations for phage studies. The capsule state of the isolation or test host can strongly influence which phages are recovered and how efficiently they plate. Whole-genome verification is equally important when interpreting phenotypes from ordered mutant libraries, particularly when surface structures are involved.

  • Open Access

    Standard and imaging flow cytometry for environmental microplastic detection: progress, challenges, and future directions

    by Georgina H. Tilly-Scholes, Abbey L. K. Hutton, Anita Tarasenko, Jessica A. P. Carlson-Jones, James S. Paterson, James G. Mitchell, Oliver G. Best

  • Open Access

    Host species background, defence systems, and phage tail gene architecture shape phage infectivity in cystic fibrosis-associated Achromobacter

    by Anita Tarasenko, Bhavya Papudeshi, Van Nguyen, Susanna Rose Grigson, George Bouras, Vijini Mallawaarachchi, Kelly Hutton Abbey Louise, Renee Green, Jack Ramsay, Hamza Hajama, et al.

    Achromobacter species are emerging multidrug-resistant (MDR) pathogens in people with cystic fibrosis. Their increasing resistance has grown an interest in phage therapy as an alternative treatment strategy. However, the factors governing phage susceptibility remain poorly understood, thereby limiting the rational selection of phage candidates. Using 15 strictly lytic Achromobacter phages and 7 clinical cystic fibrosis isolates representing Achromobacter insolitus and Achromobacter xylosoxidans, we demonstrate substantial variation in infection efficiency across all 105 phage-host combinations, variation that could not be discerned from qualitative plaque assays alone. We integrated complete bacterial and phage genomes with quantitative efficiency-of-plating (EOP) assays and lineage-aware Bayesian mixed-effects modelling to show that phage infectivity in Achromobacter is governed predominantly by bacterial lineage and strain identity, accounting for 90% of total variance in log-normalised EOP, with individual strains varying substantially in permissiveness irrespective of species membership. After accounting for this lineage structure, no individual defence system, antimicrobial resistance gene class, or phage tail cluster retained a statistically significant independent or interaction association with infectivity. Together, these findings demonstrate that bacterial strain identity is the primary driver of infection outcome. Host defence systems and phage tail-associated genes remain biologically plausible contributors; their independent effect could not be resolved after accounting for lineage structure, indicating that infection outcomes are largely strain-dependent. This work shifts the question from which individual traits predict infection to how strain lineage and specific host-phage combinations jointly determine infectivity and argues that quantitative phenotyping of individual phage-host pairs is essential for guiding phage candidate selection and supporting rational cocktail design against multidrug-resistant Achromobacter infections in cystic fibrosis.

  • Open Access

    Microbial Ecological Signatures Predict Pathogen Emergence and Multidrug Resistance in Cystic Fibrosis Airways up to a Year in Advance

    by Thomas R. Goddard, Jessica Ap. Carlson-Jones, Judith Morton, Chee Y. Ooi, Andrew Tai, Morgyn S. Warner, John Wong, Ieuan Es. Evans, Emily Hopkins, Jonathan R. Iredell, et al.

    Chronic infections in cystic fibrosis (CF) emerge from gradual ecological transitions in the airway microbiome, yet early predictive markers remain poorly defined. We developed a new autoencoder-based framework that outperforms read-based or metagenome-assembled genome-based analyses at capturing the continuum from health-associated commensals to pathogen-dominated, antibiotic-tolerant communities. This improvement is achieved by integrating taxonomic and functional data from 127 sputum and bronchoalveolar lavage metagenomes from 64 people with CF into latent “Clusters of Phylogeny and Functions” (COPFs). Coupled with gradient-boosted random forests, COPFs predicted Pseudomonas aeruginosa colonisation, multidrug resistance, and impending infection up to a year before clinical detection. The multidrug-resistant P. aeruginosa signature showed the same resistance-mechanism evolution as found in laboratory experiments. The inclusion of eukaryotic markers revealed persistent Aspergillus fumigatus signatures even during culture-negative intervals. Applying our South Australian-trained model to over 1,000 global metagenomes from 22 independent CF datasets, we achieved 94% accuracy in predicting P. aeruginosa status across platforms and geographies, validating the model’s universal utility. Our results demonstrate that combining datasets with deep learning reveals conserved ecological and metabolic mechanisms in disease progression, transforming metagenomics into a predictive framework for managing chronic infections.


  • Open Access

    Reprogramming resistance: phage-antibiotic synergy targets efflux systems in ESKAPEE pathogens

    by Anita Tarasenko, Bhavya N. Papudeshi, Susanna R. Grigson, Vijini Mallawaarachchi, Abbey L. K. Hutton, Morgyn S. Warner, Jeremy J. Barr, Jon Iredell, Bart Eijkelkamp, Robert A. Edwards

    Multidrug-resistant (MDR) and extensively drug-resistant (XDR) ESKAPE pathogens pose a significant global health threat due to their ability to evade antibiotics through intrinsic and acquired mechanisms. These bacteria, including Enterococcus faecium , Staphylococcus aureus , Klebsiella pneumoniae , Acinetobacter baumannii , Pseudomonas aeruginosa , Escherichia coli, and Enterobacter species, evade antibiotics through intrinsic and adaptive mechanisms. Common strategies include capsule formation, biofilm, β-lactamase production, and efflux activity. Using these mechanisms, bacteria can evade the effects of antibiotics, leading to persistent and difficult-to-treat infections. Understanding the mechanisms of resistance is crucial in developing effective strategies to combat MDR and XDR ESKAPEE pathogens. A promising approach is the development of alternative treatments targeting specific resistance mechanisms in these pathogens. Bacteriophages (phages), which co-evolve with bacterial hosts, offer a dynamic therapeutic alternative by targeting pathogenic bacteria using precision-based strategies. This targeted approach can overcome antibiotic resistance and reduce the risk of damaging the beneficial microbiota. Phages can restore susceptibility in previously untreatable infections by enhancing antibiotic uptake and imposing fitness costs on resistant strains. However, therapeutic deployment faces challenges such as rapid evolution of phage resistance, inconsistent production standards, and limited regulatory pathways. This review examines the mechanistic insights into phage-antibiotic synergy, with a focus on efflux pump-mediated resistance. It discusses emerging therapeutic strategies, current clinical applications, and the translational frameworks needed to integrate phage therapy into mainstream medicine and transform the clinical management of drug-resistant ESKAPEE infections.


  • Open Access

    From Crisis to Cure: Phage Therapy’s Clinical Role in Combating Multidrug-Resistant ESKAPE Pathogens

    by Anita Tarasenko, Bhavya Papudeshi, Susanna Grigson, Viji Mallawaarachchi, Abbey Hutton, Morgyn Warner, Jeremy Barr, Jonathan Iredell, Bart Eijkelkamp, Robert A. Edwards

    The global rise in antibiotic resistance poses a critical threat to healthcare, with ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) leading the charge in nosocomial infections resistant to multiple drug classes. These pathogens, often impervious to last-line antibiotics, present immense clinical challenges. Their resilience is driven by several mechanisms, including capsule formation, biofilm production, β-lactamase, and efflux pump systems, which collectively enable immune evasion and antimicrobial resistance. The high mortality rate associated with ESKAPE pathogens stresses the urgent need for alternative therapeutic strategies. Phage therapy has emerged as a promising approach, utilising bacteriophages that specifically target bacterial surface receptors, including capsules, outer membrane proteins and certain efflux pumps, to infect and kill resistant strains while preserving the host microbiome. Recent clinical case studies demonstrate the success of phage therapy in treating infections caused by MDR Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa, including phage-antibiotic combinations that have reversed resistance in previously untreatable infections. Despite promising case studies, challenges remain, including phage-resistant variants, regulatory hurdles, and scalable production. This review explores the transformative potential of phage therapy against ESKAPE pathogens, highlighting recent breakthroughs, current limitations, and future prospects. As the threat of antimicrobial resistance intensifies, phage therapy represents a critical tool in the fight against MDR ESKAPE pathogens.

  • Open Access

    Picobirnavirus: How do you find where it’s hiding?

    by Abbey Hutton, Susanna Grigson, Louise Bartle, Viji Mallawaarachchi, Anita Tarasenko, James Mitchell, Robert A. Edwards

    Picobirnaviruses (PBVs) are double-stranded RNA viruses found in a wide range of hosts including humans, animals, invertebrates and birds. First discovered in 1988 from a human stool sample, PBVs were initially considered human pathogens associated with gastrointestinal illness. However, PBV has not been definitively linked to any specific disease. The nature of their pathogenicity remains unclear, raising questions as to whether PBVs are true pathogens, opportunistic pathogens or merely bystanders. The PBV genome contains extremely high levels of genetic diversity within and between sequences, as well as in the genetic codes used for translation, leading to speculation that the virus may be prokaryotic. Several methods are currently used to detect and characterise PBV genomes. In this review, we summarise the contemporary methods used to attempt host identification, highlighting the current challenges of the methods. The methods include direct culturing, PCR, next-generation metagenomics sequencing, and cloning into bacteria. Uncovering the host could elucidate PBVs' role in both human and animal health and the broader implications within various important ecosystems.


  • Open Access

    Sphae: an automated toolkit for predicting phage therapy candidates from sequencing data

    by Bhavya Papudeshi, Michael J Roach, Vijini Mallawaarachchi, George Bouras, Susanna R Grigson, Sarah K Giles, Clarice M Harker, Abbey L K Hutton, Anita Tarasenko, Laura K Inglis, et al.

    Motivation: Phage therapy offers a viable alternative for bacterial infections amid rising antimicrobial resistance. Its success relies on selecting safe and effective phage candidates that require comprehensive genomic screening to identify potential risks. However, this process is often labor intensive and time-consuming, hindering rapid clinical deployment. Results: We developed Sphae, an automated bioinformatics pipeline designed to streamline the therapeutic potential of a phage in under 10 minutes. Using Snakemake workflow manager, Sphae integrates tools for quality control, assembly, genome assessment, and annotation tailored specifically for phage biology. Sphae automates the detection of key genomic markers, including virulence factors, antimicrobial resistance genes, and lysogeny indicators such as integrase, recombinase, and transposase, which could preclude therapeutic use. Among the 65 phage sequences analyzed, 28 showed therapeutic potential, 8 failed due to low sequencing depth, 22 contained prophage or virulent markers, and 23 had multiple phage genomes. This workflow produces a report to assess phage safety and therapy suitability quickly. Sphae is scalable and portable, facilitating efficient deployment across most high-performance computing and cloud platforms, accelerating the genomic evaluation process. Availability and implementation: Sphae source code is freely available at https://github.com/linsalrob/sphae, with installation supported on Conda, PyPi, Docker containers.


  • Open Access

    Phage therapy candidates from Sphae: An automated toolkit for predicting sequencing data

    by Bhavya Papudeshi, Michael J. Roach, Vijini Mallawaarachchi, George Bouras, Susanna R. Grigson, Sarah K. Giles, Clarice M. Harker, Abbey L. K. Hutton, Anita Tarasenko, Laura K. Inglis, et al.

    Motivation: Phage therapy is a viable alternative for treating bacterial infections amidst the escalating threat of antimicrobial resistance. However, the therapeutic success of phage therapy depends on selecting safe and effective phage candidates. While experimental methods focus on isolating phages and determining their lifecycle and host range, comprehensive genomic screening is critical to identify markers that indicate potential risks, such as toxins, antimicrobial resistance, or temperate lifecycle traits. These analyses are often labor-intensive and time-consuming, limiting the rapid deployment of phage in clinical settings. Results: We developed Sphae, an automated bioinformatics pipeline designed to streamline therapeutic potential of a phage in under ten minutes. Using Snakemake workflow manager, Sphae integrates tools for quality control, assembly, genome assessment, and annotation tailored specifically for phage biology. Sphae automates the detection of key genomic markers, including virulence factors, antimicrobial resistance genes, and lysogeny indicators like integrase, recombinase, and transposase, which could preclude therapeutic use. Benchmarked on 65 phage sequences, 28 phage samples showed therapeutic potential, 8 failed during assembly due to low sequencing depth, 22 samples included prophage or virulent markers, and the remaining 23 samples included multiple phage genomes per sample. This workflow outputs a comprehensive report, enabling rapid assessment of phage safety and suitability for phage therapy under these criteria. Sphae is scalable, portable, facilitating efficient deployment across most high-performance computing (HPC) and cloud platforms, expediting the genomic evaluation process. Availability: Sphae is source code and freely available at https://github.com/linsalrob/sphae , with installation supported on Conda, PyPi, Docker containers.


  • Open Access

    Phables: from fragmented assemblies to high-quality bacteriophage genomes

    by Vijini Mallawaarachchi, Michael J Roach, Przemyslaw Decewicz, Bhavya Papudeshi, Sarah K Giles, Susanna R Grigson, George Bouras, Ryan D Hesse, Laura K Inglis, Abbey L K Hutton, et al.

    Motivation: Microbial communities have a profound impact on both human health and various environments. Viruses infecting bacteria, known as bacteriophages or phages, play a key role in modulating bacterial communities within environments. High-quality phage genome sequences are essential for advancing our understanding of phage biology, enabling comparative genomics studies and developing phage-based diagnostic tools. Most available viral identification tools consider individual sequences to determine whether they are of viral origin. As a result of challenges in viral assembly, fragmentation of genomes can occur, and existing tools may recover incomplete genome fragments. Therefore, the identification and characterization of novel phage genomes remain a challenge, leading to the need of improved approaches for phage genome recovery. Results: We introduce Phables, a new computational method to resolve phage genomes from fragmented viral metagenome assemblies. Phables identifies phage-like components in the assembly graph, models each component as a flow network, and uses graph algorithms and flow decomposition techniques to identify genomic paths. Experimental results of viral metagenomic samples obtained from different environments show that Phables recovers on average over 49% more high-quality phage genomes compared to existing viral identification tools. Furthermore, Phables can resolve variant phage genomes with over 99% average nucleotide identity, a distinction that existing tools are unable to make. Availability and implementation: Phables is available on GitHub at https://github.com/Vini2/phables.